Search Results

You are looking at 121 - 130 of 184 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

James O. Armitage, William C. Wood, and Dan L. Longo

-conserving surgery plus radiation therapy in DCIS are available. Several studies compare local excision to local excision plus whole-breast radiation (with or without tamoxifen), 9 and all showed improved local control with the addition of whole-breast radiation

Full access

Donna Trauth and Lori J. Goldstein

. Effects of radiotherapy and surgery in early breast cancer – An overview of the randomized trials . N Engl J Med 1995 ; 333 : 1444 – 1456 . 2 Early Breast Cancer Trialists'Collaborative Group . Effects of adjuvant tamoxifen and of cytotoxic

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma, and Matthew J. Ellis

metastases were diagnosed and changing from letrozole to tamoxifen produced disease stabilization. In May 2011, massive hepatic progression was noted, with obstructive jaundice, ascites, and pleural effusion. Treatment with capecitabine and intensive

Full access

Azeez Farooki

, exemestane, and letrozole) have been shown to increase the risk of fracture compared with tamoxifen. Osteoporotic fracture is a concern in men, because up to 25% of men older than 50 suffer one, he added. ADT appears to increase the risk of fracture in men

Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia

the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group . J Clin Oncol 2006 ; 24 : 3381 – 3387 . 16801628 2. Houghton J , George WD , Cuzick J , . Radiotherapy and tamoxifen in women with completely excised ductal carcinoma

Full access

Julia C. Shih and Anthony J. Olszanski

. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1

Full access

Paul C. Hendrie and David A. Garcia

cancer mortality is not known. Other factors, such as venous stasis from vessel compression, immobility, central venous catheters (CVC), and thrombogenic anticancer therapies, such as tamoxifen and thalidomide, play a role in some patients. The new agents

Full access

Joyce Liu and Ursula Matulonis

Carrasco EM . Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research . Gynecol Oncol 2002 ; 84 : 201 – 209 . 45. del Carmen MG Fuller AF Matulonis

Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

Cuzick J Wale C . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol 2010

Full access

Kathleen Harnden and Kimberly Blackwell

%) received chemotherapy. In both Z-FAST and ZO-FAST, patients were concurrently treated with letrozole. In ABCSG-12, patients were treated with ovarian suppression and either anastrozole or tamoxifen. The AZURE patients were on a variety of standard adjuvant